<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072007</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 34/02</org_study_id>
    <secondary_id>EU-20321</secondary_id>
    <nct_id>NCT00072007</nct_id>
  </id_info>
  <brief_title>Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL</brief_title>
  <official_title>2-CDA and Rituximab as Remission Induction and Rituximab as In Vivo Purging Prior to Peripheral Stem Cell Mobilization in Patients With Chronic Lymphocytic Leukemia (CLL) - A Prospective Multicenter Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cladribine, use different ways to stop cancer&#xD;
      cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab,&#xD;
      can locate cancer cells and either kill them or deliver cancer-killing substances to them&#xD;
      without harming normal cells. Combining cladribine with rituximab may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving cladribine and rituximab as&#xD;
      remission induction therapy together with rituximab and stem cell mobilization in treating&#xD;
      patients with chronic lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy and tolerability of cladribine and rituximab as remission&#xD;
           induction therapy in patients with chronic lymphocytic leukemia.&#xD;
&#xD;
        -  Determine the complete remission rate in patients treated with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the very good partial remission rate and nodular partial remission rate in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen, in terms of hemotoxicity and infection rate, in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the efficacy of in vivo purging with rituximab measured by immunophenotyping&#xD;
           in these patients.&#xD;
&#xD;
        -  Determine the feasibility of stem cell harvest in these patients after treatment with&#xD;
           this induction therapy regimen and in vivo purging with rituximab.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Remission induction: Patients receive cladribine subcutaneously (SC) on days 1-5. During&#xD;
           courses 2-4, patients also receive rituximab IV on day 1. Treatment repeats every 28&#xD;
           days for up to 4 courses in the absence of unacceptable toxicity. If unacceptable&#xD;
           toxicity persists, patients receive rituximab alone.&#xD;
&#xD;
      Patients not achieving a complete remission (CR), very good partial remission (VGPR), or&#xD;
      nodular partial remission (NPR) receive CHOP chemotherapy comprising cyclophosphamide IV,&#xD;
      doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Treatment&#xD;
      repeats every 21 days for up to 4 courses or until patients achieve a CR, VGPR, or NPR.&#xD;
&#xD;
      Patients achieving a CR, VGPR, or NPR proceed to stem cell mobilization and in vivo purging.&#xD;
&#xD;
        -  Stem cell mobilization and in vivo purging: Beginning 8-10 weeks after the first day of&#xD;
           the last course of remission induction or CHOP, patients receive rituximab IV on days 1&#xD;
           and 8, cyclophosphamide IV over 4 hours on day 2, and filgrastim (G-CSF) SC daily&#xD;
           beginning on day 4 and continuing until the last day of apheresis. Patients undergo&#xD;
           apheresis on days 11-14.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 17-41 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete-remission rate after induction</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Very good partial remission and nodular partial remission after induction</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (hematotoxicity and infection rate) at 30 days following study treatment</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">43</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>filgrastim</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>rituximab</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP regimen</intervention_name>
    <description>CHOP regimen</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cladribine</intervention_name>
    <description>cladribine</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>cyclophosphamide</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>doxorubicin hydrochloride</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>prednisone</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>vincristine sulfate</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of B-cell chronic lymphocytic leukemia (CLL)&#xD;
&#xD;
               -  CD5 positive and CD23 positive&#xD;
&#xD;
               -  Binet stage B, C, or progressive A&#xD;
&#xD;
          -  Newly diagnosed disease OR no more than 1 prior alkylating agent regimen (e.g.,&#xD;
             chlorambucil or cyclophosphamide with or without prednisone)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 65&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  No autoimmune hemolytic anemia&#xD;
&#xD;
          -  No immune thrombocytopenia&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN*&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN* NOTE: *Unless clearly related to CLL liver&#xD;
             involvement&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction at least 50%&#xD;
&#xD;
          -  No severe heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No significant arrhythmia requiring chronic treatment&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 months after study&#xD;
             participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No positive Coombs' test&#xD;
&#xD;
          -  No history of significant neurologic or psychiatric disorders, including psychotic&#xD;
             disorders or dementia&#xD;
&#xD;
          -  No seizure disorder&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             adequately treated carcinoma in situ of the cervix&#xD;
&#xD;
          -  No prior allergic reaction or hypersensitivity to study drugs or attributed to&#xD;
             compounds of similar chemical or biological composition to study drugs or other study&#xD;
             agents&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No gastric ulcers&#xD;
&#xD;
          -  No active autoimmune disease&#xD;
&#xD;
          -  No alcohol or drug abuse&#xD;
&#xD;
          -  No other concurrent serious underlying medical condition that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior purine analogs (e.g., cladribine or fludarabine)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior clinical trial participation&#xD;
&#xD;
          -  No other concurrent experimental drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reinhard Zenhaeusern, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitaeler Chur AG</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital, Luzerne</name>
      <address>
        <city>Luzerne</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital des Cadolles, Neuchatel</name>
      <address>
        <city>Neuchatel</city>
        <zip>2000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Beretta</name>
      <address>
        <city>Rheinfelden</city>
        <zip>4310</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum</name>
      <address>
        <city>Zurich</city>
        <zip>8038</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Leupin N, Schuller JC, Solenthaler M, Heim D, Rovo A, Beretta K, Gregor M, Bargetzi MJ, Brauchli P, Himmelmann A, Hanselmann S, Zenhäusern R. Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). Leuk Lymphoma. 2010 Apr;51(4):613-9. doi: 10.3109/10428191003624231.</citation>
    <PMID>20218808</PMID>
  </results_reference>
  <results_reference>
    <citation>Leupin N, Schuller JC, Solenthaler M, et al.: The combination of 2-CDA and rituximab in patients with chronic lymphocytic leukemia (CLL): a prospective multicenter phase II trial (SAKK 34/02). [Abstract] Blood 110 (11): A-2057, 2007.</citation>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

